



January 29, 2026

**The General Manager**

Pakistan Stock Exchange Limited  
Stock Exchange Building,  
Stock Exchange Road,  
Karachi

**Subject: Material Information**

**Dear Sir,**

Under Section 96 of the Securities Act, 2015 and Clause 5.6.1(a) of the Rule Book of Pakistan Stock Exchange Limited.

**Macter International Limited ("the Company")** is pleased to inform that the Company has successfully launched **TirzaTrim (Tirzepatide) in a multidose pre-filled pen (PFP) presentation.**

**Tirzepatide** is a **dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist**, indicated for the management of **Type 2 Diabetes Mellitus**, with additional benefits in **glycemic control and weight reduction**. It represents a next-generation incretin-based therapy with significant clinical relevance in cardio-metabolic care.

The launch of **TirzaTrim Multidose Pre-Filled Pen** marks an important milestone in the Company's biotechnology portfolio and further strengthens Macter's position in **advanced injectable drug delivery systems** and **complex biologics** within Pakistan.

This development reflects the Company's continued commitment to introducing innovative, patient-centric therapies and expanding access to globally benchmarked treatments in the local market.

Yours truly,

For and on behalf of

Macter International Limited

Asif Javed  
Company Secretary

CC: Director/HOD  
Supervision Division  
Securities & Exchange Commission of Pakistan  
NIC Building, 63 Jinnah Avenue, Blue Area,  
Islamabad